B+
Bull case
25%
Probability
Target price
$255.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
RMD
ResMedBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$230.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$185.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+68.2
Score
AI commentary
Official earnings coverage is constructive, supported by revenue growth, adjusted EPS growth, cash generation, capital returns, and portfolio actions [#SEC-8K-2026-08-06]. The August 7 adjusted close is available, but a reliable post-print price reaction and company-specific analyst revisions were not confirmed. Social, options, short-interest, and employee-rating data are unavailable; the report therefore remains a cautious monitoring view rather than a high-conviction rerating thesis.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence; peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-08-06eventFY2026 Q4 results modestly exceeded stored pre-print expectationsMedium impact
ResMed reported Q4 revenue of $1.464 billion and non-GAAP diluted EPS of $2.95, versus stored pre-print estimates of $1.46 billion and $2.90. Management also reported 9% revenue growth, 90 bps non-GAAP gross-margin expansion, and FY2027 capital-return guidance above $1.85 billion [#SEC-8K-2026-08-06] [#PR-EARNINGS-2026-07-31].
2026-11-06eventMatrixCare divestiture closingMedium impact
The MatrixCare sale is expected to close during ResMed's fiscal Q1 2027, subject to regulatory approvals and customary conditions. Successful completion could sharpen focus on sleep, breathing, and connected home-care markets, but timing and financial impact remain uncertain [#SEC-8K-2026-07-07] [#SEC-8K-2026-08-06].
2027-08-08catalystCore sleep-health growth and capital returnsHigh impact
The company enters FY2027 with record Q4 revenue, FY2026 revenue growth of 10%, $1.65 billion of free cash flow, new product launches, the completed Noctrix acquisition, and a 10% dividend increase. Execution and sustained demand remain the key long-term validation points [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology